Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences

Go back to Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences

Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States

December 8, 2022 4:04 PM EST

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each ADS representing one ordinary share. All ADSs to be sold in the proposed... More